Houston-based MD Anderson Cancer Center’s hemovigilance unit was born from a blood transfusion-related event that led to a patient’s death in 2019. Kimberly Klein, MD, medical director of the unit, presented operational insights from the program at the Association for the Advancement of Blood & Biotherapies annual meeting Oct. 19, according to a news release from the association.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
